Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NP87
UPID:
DPOLM_HUMAN
Alternative names:
Terminal transferase
Alternative UPACC:
Q9NP87; D3DVK4; Q6P5X8; Q86WQ9
Background:
DNA-directed DNA/RNA polymerase mu, also known as Terminal transferase, plays a crucial role in the repair of DNA double-strand breaks through non-homologous end joining (NHEJ). It is instrumental in the immunoglobulin light chain gene rearrangement during V(D)J recombination, a process vital for the diversity of the immune response.
Therapeutic significance:
Understanding the role of DNA-directed DNA/RNA polymerase mu could open doors to potential therapeutic strategies. Its involvement in DNA repair and immune system development positions it as a key target for enhancing genomic stability and treating immunodeficiencies.